Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 156,079 229,843 273,203 611,547
Total Sell Value $13,472,349 $20,340,408 $24,241,430 $58,103,504
Total People Sold 5 5 6 7
Total Sell Transactions 13 19 25 55
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 1313
  Page 12 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Guyer Charles Greg EVP, Chief Technical Officer   •       –      –    2021-04-30 4 A $62.41 $13,792 D/D 221 45,681     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-04-30 4 A $62.41 $21,281 D/D 341 68,781     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-04-30 4 OE $37.46 $37,460 D/D 1,000 303,498     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-04-23 4 AS $79.34 $793,400 D/D (10,000) 302,498     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-04-23 4 OE $26.49 $264,900 D/D 10,000 312,498     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-04-22 4 AS $78.91 $789,100 D/D (10,000) 302,498     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-04-22 4 OE $26.49 $264,900 D/D 10,000 312,498     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-04-19 4 AS $79.58 $215,582 D/D (2,709) 68,440     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-04-19 4 OE $26.49 $71,761 D/D 2,709 71,149     -
   Lawlis V Bryan Director   –       •      –    2021-04-15 4 AS $76.90 $576,750 D/D (7,500) 18,850     -
   Lawlis V Bryan Director   –       •      –    2021-04-15 4 OE $26.49 $198,675 D/D 7,500 26,350     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-04-08 4 AS $78.81 $121,131 D/D (1,537) 58,250     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2021-04-01 4 AS $76.30 $434,300 D/D (5,692) 31,016     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-03-30 4 AS $74.79 $123,553 D/D (1,652) 59,787     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-03-24 4 AS $76.30 $90,110 D/D (1,181) 61,439     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-03-22 4 D $78.52 $118,801 D/D (1,513) 62,620     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-22 4 D $78.52 $433,352 D/D (5,519) 302,498     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2021-03-22 4 D $78.52 $40,516 D/D (516) 36,708     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-03-22 4 D $78.52 $109,221 D/D (1,391) 68,440     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2021-03-22 4 D $78.52 $192,688 D/D (2,454) 106,142     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-03-18 4 AS $77.99 $102,011 D/D (1,308) 64,133     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-03-16 4 D $77.21 $429,210 D/D (5,559) 308,017     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-03-16 4 D $77.21 $96,667 D/D (1,252) 69,831     -
   Acosta Andrea GVP, Chief Accounting Officer   •       –      –    2021-03-16 4 D $77.21 $29,263 D/D (379) 18,136     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-03-16 4 D $77.21 $99,369 D/D (1,287) 65,441     -
  1313 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 12 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us